Investors

• Announcements
• 2013
• 2012
• 2011
• 23: Amendments for the Interim Financial Report for Q3 2011 for the BioPorto Group
• 22: Financial calendar 2012
• 21: CCH’s European NGAL urine patent revoked after a decision in the opposition case
• 20: Interim Financial Report for Q3 2011 for the BioPorto Group
• 19: Withdrawal of the medicine Xigris from the market
• 18: Issuance of BioPorto’s APC-PCI patent in the US
• 17: Share Capital and Votes
• 16: Increase of the share capital through a cash issue, private placement
• 15: BioPorto’s NGAL cut-off patent, status of opposition case in EU
• 14: Interim Report for Q2 2011 for the BioPorto Group
• 13: FDA accepts The NGAL Test™ for review
• 12: BioPorto’s NGAL cutoff patent is issued in India
• 11: Interim report Q1 2011
• 10: BioPorto’s NGAL cutoff patent is issued in Japan
• 09: Share capital and votes
• 08: Insider’s dealings
• 07: Issue of warrants in BioPorto A/S
• 06: Increase of share capital following exercise of warrants and conversion of bonds
• 05:Development of Annual General Meeting
• 04: Annual General Meeting
• 03: Annual report 2010
• 02: BioPorto sells NGAL license to major diagnostic company
• 01: BioPorto launches The NGAL Test™ for diagnostic use
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• Presentations
• Key Figures
• Financial Calendar 2013
• Analyst coverage
• Company Documents
• News mail
• Contact investor relations